Kornimate/medical-research-clean huggingface dataset:
long term outcome after serial lidocaine infusion in peripheral neuropathic pain

Conditions: Peripheral Neuropathy

Summary: the purpose of this study to evaluated long term outcome after serial lidocaine infusion when compared with placebo in peripheral neuropathic pain patients in acute stage (less than 6 months) at 3 months after first time of infusion

peripheral nerve injury may give rise to severe and long-lasting types of pains which are often resistant to treatment such as opioid, tricyclic antidepressant or anticonvulsant. lidocaine infusion has been the one of intractable neuropathic pain treatment . my hypothesis the serial lidocaine infusion can adequate pain control and can prevent chronic pain (central sensitisation). therefore, we designed this prospective, randomised, double-blind, controlled study to evaluate the efficacy of serial lidocaine infusion in peripheral neuropathic pain compared with placebo in long term outcome (at 3 month).

Eligibility criteria:
inclusion criteria: * peripheral neuropathic pain from peripheral nerve injury within 6 months after injury * well understand to thai language in writing or listening exclusion criteria: * underlying heart disease or arrhythmia * allergy to lidocaine, gabapentin, carbamazepine, tramadol * history of epilepsy * history of lidocaine used * underlying psychiatric disease * history of drug abuse * pregnancy and nursing

Keywords: peripheral neuropathy
24-hour urinary electrolyte excretion in chronic kidney disease

Conditions: Chronic Kidney Diseases; Electrolyte Imbalance

Summary: association between excretion pattern and development trajectory of urinary electrolytes (urine sodium, urine potassium, urine chlorine, urine magnesium, urine calcium, urine phosphorus, urine creatinine, urea, uric acid, urine glucose, urine protein, urine retinol) and adverse prognosis in patients with chronic kidney disease


Eligibility criteria:
inclusion criteria: * our study is a retrospective cohort study. the study included patients with adult（age≥18years）ckd who were hospitalized in the department of nephrology, first medical center of chinese pla general hospital from january 2014 to july 2022. patients with ckd who had one or more 24-hour urinary electrolyte excretion tests at intervals of more than three months were included in the subgroup analysis. exclusion criteria: * patients with hemodialysis therapy and urine volume less than 500ml were excluded.
efficacy of sodium heparin for prophylaxis of venous thromboembolism in surgical patients

Conditions: Venous Thromboembolism

Summary: the aim of this study is to verify, through clinical examination and doppler, the non-inferiority of the drug test (heparin sodium 5.000ui/0.25 ml - hipolabor) in relation to the drug compared (heparin sodium 5.000usp/ml - app) in preventing the development of venous thromboembolism (vte) in patients undergoing surgery for medium risk for the development of this pathology.


Eligibility criteria:
inclusion criteria: * accept all items described in ic signing it in two ways; * be aged between 18 and 60; * be alert to the need for surgery antithrombotic prophylaxis; * be classified as "moderate risk" for developing vte, according to the protocol of prophylaxis of deep vein thrombosis of the brazilian society of angiology and vascular surgery. exclusion criteria: * acute coronary syndrome, it will make use of anticoagulation; * immobilization of the lower limbs due to fractures, because in this way will be considered as high risk; * history of recent stroke; * patients at high risk of bleeding in which the use of heparin is contra-indicated; * general surgery in patients over 60 years in the case of patients at high risk for vte; * general surgery in patients 40 to 60 years with additional risk factors for development of vte; * major amputations; * more orthopedic surgeries; * patients with pre-surgical diagnosis of malignant neoplasms; * patients with a platelet level below 100x109 / l; * use of anticoagulants 48 hours before randomization; * severe liver failure; * be classified as "low risk" or "high risk" for developing vte, according to maffei et al. (2005); * pregnancy and lactation.
the effect of standard cognitive-behavioral therapy+transcranial alternating current on refractory insomnia disorder

Conditions: Insomnia

Summary: the main purpose of this study is to investigate the efficacy of cbti + transcranial alternating current (tac) technology in the treatment of refractory insomnia and the mechanism of 'cognitive-behavioural-brain network' interactions.

difficult to treat insomnia is a sleep disorder that significantly reduces the quality of sleep for patients, seriously affecting their daily work and study. at present, the main treatment method for refractory insomnia in clinical practice is drug therapy. the problems with drug therapy mainly include easy recurrence after discontinuation and the need for long-term or even lifelong medication. however, tolerance or other adverse reactions limit its long-term use. in recent years, studies have shown that cognitive-behavioral therapy and transcranial alternating current stimulation are effective in treating chronic insomnia, prolonging sleep time and improving sleep quality. however, there have been no reports on the efficacy and safety of cbti combined with tacs in the treatment of refractory insomnia. based on the important role of tacs in regulating cortical excitability and spontaneous eeg activity, as well as the precise efficacy of cbti in improving insomnia, we plan to use cbti combined with tacs to treat refractory insomnia disorders, in order to improve the effectiveness of treatment. this study adopts a randomized double-blind controlled trial to investigate the efficacy and safety of cbt+tacs in the treatment of refractory insomnia, aiming to provide a basis for clinical data of cbt+tacs in the treatment of refractory insomnia.

Eligibility criteria:
inclusion criteria: 1. meets the diagnostic criteria for insomnia in dsm-5; 2. pittsburgh sleep quality index (psqi) total score\>5 points; 3. age ≥ 18 years old, with a junior high school education or above; 4. voluntarily participate in this study and sign an informed consent form. exclusion criteria: 1. individuals with severe physical or mental illnesses are at risk of suicide; 2. clinically diagnosed or suspected sleep breathing disorders, restless leg syndrome, and sleep wake rhythm disorders, as well as workers on rotating shifts; 3. pregnant and lactating women; 4. currently undergoing any psychological therapy.

Keywords: standard cognitive behavioural therapy tacs treatment-resistant insomnia
a study of orforglipron (ly3502970) in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone

Conditions: Type 2 Diabetes

Summary: the main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. the study will last approximately 54 weeks.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes * have hba1c ≥7.0% (53 mmol/mol) to ≤9.5% (80 mmol/mol) despite diet and exercise treatment, as determined by the central laboratory at screening. * are naïve to insulin therapy except for gestational diabetes or ≤14 days use for acute treatment and have not used any oral or injectable antihyperglycemic medications during the 90 days preceding screening or between screening and randomization. * are of stable weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight other than the lifestyle and/or dietary measures for diabetes treatment. * have a body mass index (bmi) ≥23.0 kilogram/square meter (kg/m²) at screening. exclusion criteria: * have type 1 diabetes * have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening, or between screening and randomization. * currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * have new york heart association functional classification iv congestive heart failure. * have acute or chronic pancreatitis
high-intensity interval training on pre-hypertensive subjects

Conditions: Metabolism Disorder; Hypertension

Summary: despite exercise training decrease blood pressure in 'average' terms, there is a wide interindividual variability after exercise training, being yet unknown what mode of exercise (e.g. endurance, strength, concurrent, or high intensity interval training) produce more/less non-responder (nr) prevalence (i.e., percentage of subjects who experienced a non-change/worsened response after training in some outcome).

despite exercise training decrease blood pressure in 'average' terms, there is a wide interindividual variability after exercise training, being yet unknown what mode of exercise (e.g. endurance, strength, concurrent, or high intensity interval training) produce more/less non-responder (nr) prevalence (i.e., percentage of subjects who experienced a non-change/worsened response after training in some outcome).

Eligibility criteria:
inclusion criteria: * written informed consent; * interested in improving health and fitness; * systolic blood pressure \> 120 mmhg and \< 140 mmhg, and/or dbp ≥ 80 and \< 90 mmhg according with standard classification; * no drug therapy during the previous 3 months; * body mass index (bmi) 25 and 35 kg/m2); (c) physically inactive (according to the international physical activity questionnaire previously validated in chilean population) * normal /mild altered lipid profile (total cholesterol \[tc\] \~200 and ≤250 mg/dl, low-density lipids \[ldl-c\] \~140 mg/dl and ≤200 mg/dl, high-density lipids \[hdl-c\] ≥20 and \~40 mg/dl, triglycerides \~150 and ≤250 mg/dl) according with standard classification. exclusion criteria: * cardiovascular contraindications to exercise histories of stroke; * asthma and chronic obstructive pulmonary disease; * musculoskeletal disorder such as low back pain; * smokers in the last 3 months were not included in the study.
effects of the mechanical peripheral stimulation for parkinson's disease rehabilitation

Conditions: Parkinson's Disease

Summary: the purpose of this study is to evaluate safety and effectiveness of the peripheral mechanical stimulation of the feet on gait variables, clinical status, risk of falls, bdnf levels, immunological profile and brain functional connectivity changes in patients with parkinson's disease.

patients will be submitted to 8 sessions of peripheral mechanical stimulation of the feet or sham stimulation along 4 weeks. evaluations will be performed before and after the first session, after the forth and the eighth session.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease based on clinical criteria, dopamine transporter (dat) scans and/or magnetic resonance imaging; * able to walk 25 feet unassisted or with minimal assistance; * presenting freezing of gait; * aged between 50-85 years; * minimum score of 20 in the mini mental state examination (mmse); exclusion criteria: * secondary musculoskeletal disorder involving the lower limb, as chondral injuries, ligament and ankle sprains which may impede the realization of the gait by pain or motion disability; * peripheral neuropathy; * not attending all the treatment; * absolute contraindications for fmri (just for fmri examination); * presence of deep brain stimulation;
clinical value of breast high-resolution mr ductography in patients with pathological nipple discharge

Conditions: Breast Neoplasms; Nipple Discharge

Summary: nipple discharge is one of the common symptoms of breast disease patients. nipple discharge can be divided into physiological and pathological nipple discharge (pnd). among patients with pnd symptoms who undergo biopsy, 5%-21% of them are malignant, and the risk of malignancy increases with age. the primary diagnostic imaging methods for pnd patients include mammography and breast ultrasound. nearly half of pnd patients who undergo traditional mammography and ultrasound examination have negative findings, but this does not rule out the presence of malignant lesions. central duct excision is the gold standard for pnd diagnosis, but invasive surgery without imaging guidance can lead to some complications. magnetic resonance ductography (mrd), which uses water imaging technology to visualize the inside of the duct without contrast injection, can show imaging features of ductal lesions such as filling defects, irregularities of duct walls, and ductal obstruction. however, previous studies have shown that the signal-to-noise ratio of mrd images needs to be improved. microscopy coil has the characteristics of small voxels and high spatial resolution, making it suitable for high signal-to-noise ratio imaging of small superficial structures. this provides a hardware foundation for improving the quality of mrd images. therefore, in this study, the investigators aim to use the 3t mr instrument and microscopy coil to perform non-invasive high-resolution magnetic resonance ductography (hr-mrd) on pnd patients to evaluate the ability of hr-mrd to detect pnd causes and the imaging features of duct-related lesions on hr-mrd, to assist in the accurate diagnosis and treatment of pnd.


Eligibility criteria:
inclusion criteria: * female patients aged between 18 and 75 years old. * pathological nipple discharge patients who received treatment at sun yat-sen memorial hospital. the diagnostic criteria for pathological nipple discharge include unilateral, single duct orifice, and spontaneous discharge of serous or bloody fluid. patients who meet any of the above criteria are considered as pathological discharge. * willing to sign an informed consent form for clinical research and undergo hr-mrd and mrd examination. exclusion criteria: * patients who have undergone surgery on the nipple-areolar complex of the pnd breast side within the past year. * patients who have claustrophobia or metal implants in their body, which are not suitable for mri scans. * patients who are pregnant or breastfeeding.
collaborative care for depression and diabetic retinopathy in african americans

Conditions: Diabetic Retinopathy

Summary: in this feasibility/pilot study, we will develop, refine, and evaluate the feasibility of a novel mental health/ophthalmologic intervention called, "collaborative care for depression and diabetic retinopathy" (cc-ddr), which aims to treat depression and lower hba1c in older african americans with mild-to-moderate diabetic retinopathy (dr) and comorbid depression.

the specific aims are: 1. to develop the cc-ddr treatment protocol. this will involve: 1. creating an initial version of the cc-ddr treatment protocol. 2. refining the protocol based on input from an expert panel with expertise in dr, depression, and culturally relevant interventions for diabetes in older african americans. 3. developing a tool to assess interventionist treatment adherence and competence. 2. to conduct an open trial of cc-ddr with 40 participants who have poorly controlled diabetes, depression, and mild or moderate dr. during this open trial we will: 1. evaluate the feasibility of cc-ddr. 2. refine the cc-ddr treatment protocol by incorporating feedback from participants, community health care workers (chws), ophthalmologists, and the expert panel. 3. refine procedures for recruitment and retention, outcome assessment, monitoring treatment fidelity, chw training and supervision, quality assurance, and study administration, based on input from investigators, chws, participants, and the expert panel. 4. examine cc-ddr's impact on depression severity; diabetes self-management practices; hba1c level; blood pressure; adherence to the ophthalmologist treatment plan; vision function; quality of life; and satisfaction with cc-ddr. 3. to complete a manual of procedures that characterizes all aspects of the planned efficacy trial of cc-ddr.

Eligibility criteria:
inclusion criteria: 1. african-american race 2. age ≥ 65 years 3. type 2 diabetes 4. mild or moderate nonproliferative dr with or without macular edema 5. depressive symptoms (i.e., patient health questionnaire-9 score ≥5) 6. hba1c ≥ 7.0% exclusion criteria: 1. treated proliferative dr 2. global cognitive impairment (i.e., mini mental status score ≤ 20) 3. psychiatric diagnosis other than depression 4. treatment for depression started in the previous 3 months 5. life expectancy under 2 years

Keywords: depression health disparities african american geriatric
subcutaneous ntg for us radial artery cannulation

Conditions: Morbid Obesity

Summary: clinicians are increasingly dealing with morbid obese patients. in morbid obese patients, difficult sampling and problems encountered with noninvasive blood pressure monitoring makes arterial cannulation an essential skill in many situations like surgeries or trans-radial procedures for coronary or carotid interventions. radial artery has been preferred over other sites for arterial cannulation due to low incidence of bleeding, better hemostats, more comfort, and immediate ambulation. sm in this study, subcutaneous nitroglycerin will be used to facilitate radial artery cannulation aiming to decrease insertion time, increase success rate and decrease related complications


Eligibility criteria:
inclusion criteria: * morbid obese indicated for radial artery cannuulation exclusion criteria: * +ve allen test peripheral arterial disease refusal
lithium treatment to prevent cognitive impairment after brain radiotherapy

Conditions: Cognitive Impairment; Cognitive Decline; Radiotherapy Side Effect; Radiotherapy; Complications; Brain Tumor; Memory Impairment; Late Effect of Radiation

Summary: randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (s-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors. primary outcome measure is processing speed index (psi) 2 years after start of study treatment.

late-appearing cognitive side effects after brain radiotherapy is a potential disabling condition in pediatric brain tumor survivors. it can have profound negative effects on education, career options and quality of life. there is no current interventional drug treatment to prevent this intellectual impairment after brain tumor treatment. primary objective: to assess the efficacy of lithium treatment (up to 7 years) after brain radiotherapy (both whole brain and focal) for central nervous system malignancy in preventing late-appearing cognitive processing speed impairment in children aged 5 or older. secondary objectives: * to assess the efficacy of lithium treatment through evaluation of other neuropsychological/quality of life test scores. * to assess the efficacy of lithium treatment through evaluation of radiological findings after lithium treatment using magnetic resonance imaging (mri) of the brain. exploratory objectives: to explore the feasibility, safety and tolerability of lithium treatment in this patient group, using side effect forms/adverse events (ae) reporting and laboratory measures.

Eligibility criteria:
inclusion criteria: * age \>5 years. * age \<18 years at time of radiotherapy. * has received cranial/craniospinal radiation treatment of brain tumor within the last 7 years. * adequate contraceptive method to prevent pregnancy\* during the entire lithium treatment period and six months thereafter. * negative pregnancy test\* at screening, at start of study treatment, and monthly thereafter. * written informed consent from patient and/or caregiver. exclusion criteria: * allergy/hypersensitivity to lithium or any of the excipients * renal failure (cystatin c derived glomerular filtration rate \< 60). * cardiac failure or heart disease, including brugada syndrome (or family history thereof). * uncontrolled hypothyroidism. * pregnancy or breast feeding. * severe fluid or electrolyte imbalance. * karnofsky-lansky score \< 60. * other condition deemed incompatible with inclusion in this study (estimated 2 year survival prognosis less than 25 %, expected poor protocol compliance, inability to swallow tablets, language difficulties). * inclusion in other study protocol precluding inclusion in this study.

Keywords: lithium neuroprotection neuroprotective regenerative prevention radiation pediatric brain tumor brain tumor cognition cognitive
a phase 1, first in human study of torl-4-500 in patients with advanced cancer

Conditions: Advanced Solid Tumor; Hepatocellular Carcinoma

Summary: this first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of torl-4-500 in patients with advanced cancer. for part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (acc).


Eligibility criteria:
inclusion criteria: * advanced solid tumor * measurable disease, per recist v1.1 * eastern cooperative oncology group (ecog) performance status 0-1 * adequate organ function exclusion criteria: * has not recovered \[recovery is defined as nci ctcae, version 5.0, grade ≤1\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements * received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of torl-4-500 * progressive or symptomatic brain metastases * serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection * history of significant cardiac disease * history of myelodysplastic syndrome (mds) or aml * history of another cancer within 3 years before day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. a history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (dcis) of the breast and prostate cancer with a gleason score less than or equal to 6, are also not excluded * if female, is pregnant or breastfeeding

Keywords: adc